PT93424B - Processo para a preparacao de uma composicao contendo d-cicloserina e d- -alanina para melhoria de memoria e de aprendizagem ou para tratamento de doencas psicoticas ou cognitivas - Google Patents

Processo para a preparacao de uma composicao contendo d-cicloserina e d- -alanina para melhoria de memoria e de aprendizagem ou para tratamento de doencas psicoticas ou cognitivas Download PDF

Info

Publication number
PT93424B
PT93424B PT93424A PT9342490A PT93424B PT 93424 B PT93424 B PT 93424B PT 93424 A PT93424 A PT 93424A PT 9342490 A PT9342490 A PT 9342490A PT 93424 B PT93424 B PT 93424B
Authority
PT
Portugal
Prior art keywords
cycloserine
therapeutically effective
alanine
effective amount
treatment
Prior art date
Application number
PT93424A
Other languages
English (en)
Portuguese (pt)
Other versions
PT93424A (pt
Inventor
Alexis A Cordi
Michael R Jans
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PT93424A publication Critical patent/PT93424A/pt
Publication of PT93424B publication Critical patent/PT93424B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
PT93424A 1989-03-15 1990-03-14 Processo para a preparacao de uma composicao contendo d-cicloserina e d- -alanina para melhoria de memoria e de aprendizagem ou para tratamento de doencas psicoticas ou cognitivas PT93424B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (2)

Publication Number Publication Date
PT93424A PT93424A (pt) 1990-11-07
PT93424B true PT93424B (pt) 1996-08-30

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93424A PT93424B (pt) 1989-03-15 1990-03-14 Processo para a preparacao de uma composicao contendo d-cicloserina e d- -alanina para melhoria de memoria e de aprendizagem ou para tratamento de doencas psicoticas ou cognitivas

Country Status (17)

Country Link
US (1) US5061721A (enExample)
EP (1) EP0387867B1 (enExample)
JP (1) JP2963720B2 (enExample)
KR (1) KR900013961A (enExample)
AT (1) ATE88890T1 (enExample)
AU (1) AU624917B2 (enExample)
CA (1) CA2010635C (enExample)
DE (1) DE69001503T2 (enExample)
DK (1) DK0387867T3 (enExample)
ES (1) ES2055197T3 (enExample)
FI (1) FI901289A7 (enExample)
GR (1) GR3008225T3 (enExample)
IE (1) IE64130B1 (enExample)
IL (1) IL93562A (enExample)
NO (1) NO901198L (enExample)
NZ (1) NZ232809A (enExample)
PT (1) PT93424B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
DE69434571T2 (de) * 1993-03-29 2006-08-03 Queen's University At Kingston, Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
EP0809624B1 (en) * 1995-02-15 2001-08-29 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6172041B1 (en) 1996-07-22 2001-01-09 University Of Utah Research Foundation Use of conantokins
CA2261568A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2002078615A2 (en) 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
AU2002256422A1 (en) * 2001-05-02 2002-11-11 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US20050176826A1 (en) * 2002-03-15 2005-08-11 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005014797A2 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
AU2004311869A1 (en) 2003-12-29 2005-07-21 Michael Davis Compositions and methods to treat recurrent medical conditions
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
EP2862581B1 (en) 2006-10-12 2021-08-11 BHI Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
EP2670409B1 (en) * 2011-01-31 2018-04-18 Serotech, LLC Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US9737562B2 (en) 2012-12-11 2017-08-22 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
AU2014212484B2 (en) 2013-01-29 2018-01-04 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA receptor modulators and uses thereof
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
AU2014212487C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR20150110784A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EA201990425A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
BR112022010280A2 (pt) * 2019-11-27 2022-08-16 Neurorive Inc Terapia de combinação de ciclosserina e lítio para o tratamento da depressão

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
PT93424A (pt) 1990-11-07
ATE88890T1 (de) 1993-05-15
DE69001503T2 (de) 1993-09-09
US5061721A (en) 1991-10-29
EP0387867B1 (en) 1993-05-05
IE64130B1 (en) 1995-07-12
EP0387867A1 (en) 1990-09-19
FI901289A0 (fi) 1990-03-15
NO901198D0 (no) 1990-03-14
AU624917B2 (en) 1992-06-25
CA2010635C (en) 2001-03-06
GR3008225T3 (enExample) 1993-09-30
IL93562A0 (en) 1990-11-29
IE900921L (en) 1990-09-15
JPH03148221A (ja) 1991-06-25
DE69001503D1 (de) 1993-06-09
FI901289A7 (fi) 1990-09-16
AU5073490A (en) 1990-09-20
JP2963720B2 (ja) 1999-10-18
NZ232809A (en) 1992-05-26
NO901198L (no) 1990-09-17
KR900013961A (ko) 1990-10-22
IL93562A (en) 1996-01-31
DK0387867T3 (da) 1993-06-01
CA2010635A1 (en) 1990-09-15
ES2055197T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
PT93424B (pt) Processo para a preparacao de uma composicao contendo d-cicloserina e d- -alanina para melhoria de memoria e de aprendizagem ou para tratamento de doencas psicoticas ou cognitivas
AU593051B2 (en) Method of treating alzheimer's disease
JP2020128384A (ja) 医薬溶液、調製方法及び治療的使用
US20040029941A1 (en) Zonisamide use in obesity and eating disorders
JP2011126909A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
Georgotas et al. Trazodone hydrochloride: A wide spectrum antidepressant with a unique pharmacological profile: A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology
JP2012255039A (ja) ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤
EP1558231A2 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU579028B2 (en) Anticonvulsant compositions and method
US5260324A (en) Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5266571A (en) Treatment of hemorrhoids with 5-HT2 antagonists
JP2008528532A (ja) 統合失調症のアドオン治療用ｓｐｍ９２７
EP1014974A1 (en) Treatment of schizophrenia and psychosis
PT92799B (pt) Utilizacao de um agonista parcial de glicina b, nomeadamente um composto amino-isoxazolidina, para a preparacao de um medicamento empregue como antipsicotico e processo para a preparacao de uma composicao farmaceutica contendo o referido agonista
ES2534560T3 (es) Acetato de eslicarbazepina y su uso
SK4542002A3 (en) Synergistic combinations of an NK1 receptor antagonist and a GABA structural analog
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
US4388325A (en) L-Arginine D,L-pyroglutamate as a pharmaceutical agent having an activity at the neuro-endocrinal level
WO2004045718A2 (en) Treatment of cognitive dysfunctions'
US4861772A (en) Method and composition to treat panic syndrome
JPH0232020A (ja) モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
Hamada et al. Comparison of the spinal anti-nociceptive effects of ES-242-1 and MK-801, two different NMDA antagonists, in rats
CA2327585A1 (en) Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
HU220068B (hu) Eljárás atipamezolt tartalmazó, impotencia kezelésére alkalmas gyógyászati készítmények előállítására
JP2001523720A (ja) 鎌状赤血球病、異常な細胞増殖によって特徴づけられる炎症性疾患、下痢症および伝染性下痢症の治療または予防用の置換１１−フェニル−ジベンザゼピン化合物の使用。

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19960502

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19971130